Navigation Links
Cannabis Science Announces The Depository Trust Company (DTC) Lifts Share Trading "Chill" Effective Immediately
Date:9/6/2013

COLORADO SPRINGS, Colo., Sept. 6, 2013 /PRNewswire/ -- Cannabis Science, Inc. (NASD OTC: CBIS), is proud to announce that the Depository Trust Company (DTC) has confirmed through official communication to the Company, effective immediately, it has lifted the deposit transaction restriction "Chill" and has resumed accepting and processing deposits.

Excerpt from the official DTC Letter to the Company,  "This letter is in response to your recent inquiries and submission regarding the deposit transaction restriction (the "Deposit Chill") on CUSIP 137648101 (the "Issue"), issued by Cannabis Science, Inc.

Please be advised that The Depository Trust Company has determined to lift the Deposit Chill and has resumed accepting deposits of the issue depository and book-entry transfer services."

Chad S. Johnson, Esq., Chief Operating Officer & General Counsel of Cannabis Science, stated, "This is great news and we are excited that the "Chill" has been removed.  Our entire team, especially our legal and accounting teams, worked diligently on this matter, and we are thankful for the work they have done."

Cannabis Science continues with its efforts working toward novel cannabis and cannabinoid-based drug development to treat certain infectious and age-related illnesses and skin cancers, including HIV related cancers like Kaposi's Sarcoma.

About Cannabis Science, Inc.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. The medicinal use of cannabis has an extensive history dating back thousands of years, and currently there is a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illnesses. Our initial focus is on skin and other cancers including HIV related cancers such as Kaposi's Sarcoma.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934.  A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Colorado Springs, Colorado

Dr. Dorothy Bray, CEO & Director
Dr. Robert Melamede, President & Director
Chad S. Johnson, COO, General Counsel & Director
Mario Lap, President of European Operations & Director
info@cannabisscience.com

For Investor Inquires:

Robert Kane
Vice President of Investor Relations
rkane@cannabisscience.com
+1.561.420.4824


'/>"/>
SOURCE Cannabis Science, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. X-Change Corp. Delighted with DOJs Historic Shift Toward Non-Interference Within State Cannabis Regulatory Environments; Sees Green Light for Companys Patient-Driven Medical Cannabis Operations Under State Laws
2. X-Change Corporation Signs Multi-Million Dollar Agreement for Multi-State Product Release Licensing, Medical Cannabis Dispensary Management, and Cultivation Consulting
3. American Drug War II: Cannabis Destiny is IMDBs Highest Rated 2013 Documentary
4. Cannabis Science Appoints Clinical Development Expert, Dr. Dorothy Bray, as Chief Executive Officer (CEO) and Director, Focusing on CS-TATI-1 and Building Companys Drug Development Pipeline
5. Virogens New Business Unit, "The Cannabis Connection," to Focus on High-End Medicinal Marijuana Dispensary Niche within $15-20 Billion Legal Marijuana Market
6. Virogen Announces Launch of New Business Unit, "The Cannabis Connection", and Sets Sights on $15-20 Billion Legal Marijuana Market
7. Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
8. Abattis Provides $10,000 Sponsorship to the American Herbal Pharmacopoeia for Cannabis Monograph Project
9. Optimism of Cannabis Patients Creates More Demand for Phytiva Brand of Cannabinoid Solutions as Illinois and New Hampshire Take Key Legislative Steps Toward Legalization of Medical Cannabis
10. New Study Shows Cannabis Effects on Driving Skills
11. Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Sciences Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016 /PRNewswire/ ... leading RNA medicines company, announced today that it ... to develop RNA-based therapeutics for the treatment of ... Arcturus, wholly-owned therapeutic delivery platform LUNAR™ and UNA ... "Given Takeda,s long-standing commitment to and ...
(Date:12/6/2016)... JOLLA, Calif. , Dec. 6, 2016 /PRNewswire/ ... a biopharmaceutical company leading the discovery and development ... new drug development candidates at its R&D day, ... The first candidate, RGLS5040, is an anti-miR targeting ... The second candidate, RGLS4326, is an anti-miR targeting ...
(Date:12/6/2016)... new study released today by the Alliance for ... Drug Pricing Program will continue to expand at an unprecedented ... exceed $23 billion in total purchases at the 340B price. ... Part B drug reimbursement purchases over the next five years. ... of data on total drug purchases through 340B from 2005 ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... 07, 2016 , ... ODU, a worldwide leader in ... its advanced highly customizable contact technology solutions. , ODU Single Contact Technology portfolio ... ideal for a wide range of applications that require customization from industries like ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving ... are not fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. ... to the children of the world. , In exchange for generous donations, customers will ...
(Date:12/7/2016)... , ... December 07, 2016 , ... Facial plastic surgeon, ... holiday season by donating a portion of proceeds to two local organizations: North Chicago ... Animal Control & Friends is a team of authorized and trained volunteers who ...
(Date:12/7/2016)... , ... December 07, 2016 , ... "ProBrand Flip allows ... all media," said Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip ... to use drop zones. Editors can select from a variety of flip book animations. ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a ... to the presidency and to America. “Tomorrow Trump Goes To Washington” is the creation ... she can for this country. , Nancy attributes her patriotic nature to her WWII ...
Breaking Medicine News(10 mins):